Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators. Gelderblom H, et al. Among authors: italiano a. Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3. Lancet. 2024. PMID: 38843860 Clinical Trial.
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report.
Schöffski P, Jones RL, Agulnik M, Blay JY, Chalmers A, Italiano A, Pink D, Stacchiotti S, Valverde C, Vincenzi B, Wagner MJ, Maki R. Schöffski P, et al. Among authors: italiano a. ESMO Open. 2024 Jul;9(7):103487. doi: 10.1016/j.esmoop.2024.103487. Epub 2024 Jun 28. ESMO Open. 2024. PMID: 38943735 Free PMC article. Review.
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R. Verlingue L, et al. Among authors: italiano a. EBioMedicine. 2024 Oct 11;109:105374. doi: 10.1016/j.ebiom.2024.105374. Online ahead of print. EBioMedicine. 2024. PMID: 39395231 Free article.
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics.
Cousin S, Guégan JP, Shitara K, Palmieri LJ, Metges JP, Pernot S, Fukuoka S, Koyama S, Nishikawa H, Bellera CA, Adenis A, Gomez-Roca CA, Cassier PA, Hollebecque A, Cantarel C, Kind M, Soubeyran I, Vanhersecke L, Bessede A, Italiano A. Cousin S, et al. Among authors: italiano a. Mol Cancer. 2024 Sep 13;23(1):197. doi: 10.1186/s12943-024-02092-x. Mol Cancer. 2024. PMID: 39272096 Free PMC article. Clinical Trial.
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F, Chaigneau L, Collard O, Pracht M, Henon C, Ray-Coquard I, Armoun K, Salas S, Spalato-Ceruso M, Adenis A, Verret B, Penel N, Moreau-Bachelard C, Italiano A, Dufresne A, Metzger S, Chabaud S, Perol D, Le Cesne A. Blay JY, et al. Among authors: italiano a. Ann Oncol. 2024 Sep 4:S0923-7534(24)03924-3. doi: 10.1016/j.annonc.2024.08.2343. Online ahead of print. Ann Oncol. 2024. PMID: 39241959 Free article.
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Jhaveri KL, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Schmid P, Saura C, Turner NC, Varga A, Cheeti S, Hilz S, Hutchinson KE, Jin Y, Royer-Joo S, Peters U, Shankar N, Schutzman JL, Juric D. Jhaveri KL, et al. Among authors: italiano a. J Clin Oncol. 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110. Online ahead of print. J Clin Oncol. 2024. PMID: 39236276
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Among authors: italiano a. N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394. N Engl J Med. 2024. PMID: 39231341 Clinical Trial.
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Braye F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, Andre F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: italiano a. Clin Cancer Res. 2024 Sep 3:10.1158/1078-0432.CCR-24-1834. doi: 10.1158/1078-0432.CCR-24-1834. Online ahead of print. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
539 results